Local injection of immunotherapy could be more effective than systemic

In a paper published in Science Translational Medicine, a team from Stanford University led by Ronald Levy showed that an immunotherapy treatment comprising a toll-like receptor 9 (TLR9) agonist and an agonistic antibody against tumor necrosis factor (TNF) receptor superfamily member 4 (OX40; TNFRSF4; CD134) was effective at reducing tumor burden, and that injecting the combo into tumors locally, rather than systemically, further enhanced the immune effect.

Levy was part of the team behind Rituxan rituximab, a chimeric mAb against CD20 from Biogen Inc. (NASDAQ:BIIB)...